Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To perform a double-blind, randomized study comparing efficacy and safety of daily and weekend prednisone in boys with Duchenne muscular dystrophy (DMD).
Methods: A total of 64 boys with DMD who were between 4 and 10 years of age were randomized at 1 of 12 centers of the Cooperative International Neuromuscular Research Group. Efficacy and safety of 2 prednisone schedules (daily 0.75 mg/kg/day and weekend 10 mg/kg/wk) were evaluated over 12 months.
Results: Equivalence was met for weekend and daily dosing of prednisone for the primary outcomes of quantitative muscle testing (QMT) arm score and QMT leg score. Secondary strength scores for QMT elbow flexors also showed equivalence between the 2 treatment groups. Overall side effect profiles of height and weight, bone density, cataract formation, blood pressure, and behavior, analyzed at 12 months, did not differ between weekend and daily dosing of prednisone.
Conclusions: Weekend dosing of prednisone is equally beneficial to the standard daily dosing of prednisone. Analysis of side effect profiles demonstrated overall tolerability of both dosing regimens.
Classification of evidence: This study provides Class I evidence that weekend prednisone dosing is as safe and effective as daily prednisone in preserving muscle strength and preventing body mass index increases in boys with DMD over a 12-month period.
GLOSSARY
- ANOVA=
- analysis of variance;
- BMI=
- body mass index;
- CBCL=
- Child Behavior Check List;
- CINRG=
- Cooperative International Neuromuscular Research Group;
- DEXA=
- dual-energy x-ray absorptiometry;
- DMD=
- Duchenne muscular dystrophy;
- FEV1=
- forced expiratory volume in 1 second;
- FVC=
- forced vital capacity;
- MIP=
- maximum inspiratory pressure;
- MMT=
- manual muscle testing;
- MVV=
- maximal voluntary ventilation;
- NCI=
- National Cancer Institute;
- PFT=
- pulmonary function test;
- QMT=
- quantitative muscle testing
Footnotes
-
Study funding: Supported by the Muscular Dystrophy Association (MDA), General Clinical Research Center (GCRC) 5M01 RR020359, and the NIH (K23 RR16281–01).
-
The authors take full responsibility for the contents of this article, which do not represent the views of the Department of Veterans Affairs or the United States Government.
-
Editorial, page 416
- Received March 25, 2010.
- Accepted February 10, 2011.
- Copyright © 2011 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. Dennis Bourdette and Dr. Lindsey Wooliscroft
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Special Article
Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophyReport of the Guideline Development Subcommittee of the American Academy of NeurologyDavid Gloss, Richard T. Moxley III, Stephen Ashwal et al.Neurology, February 01, 2016 -
Articles
Pentoxifylline as a rescue treatment for DMDA randomized double-blind clinical trialD.M. Escolar, A. Zimmerman, T. Bertorini et al.Neurology, March 07, 2012 -
Article
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle functionEric P. Hoffman, Benjamin D. Schwartz, Laurel J. Mengle-Gaw et al.Neurology, August 26, 2019 -
Editorials
Weekend high-dosage prednisoneA new option for treatment of Duchenne muscular dystrophyRichard T. Moxley III, Shree Pandya et al.Neurology, July 13, 2011